Drug-induced hyperglycemia

JAMA

Volumn 286, Issue 16, 2001, Pages 1945-1948

  Luna, Beatriz ^a,b   Feinglos, Mark N ^c  

^a Campbell University   (United States)

^b DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOZAPINE; CORTICOSTEROID; INSULIN; METFORMIN; METOPROLOL; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; PENTAMIDINE; PIOGLITAZONE; PROTEINASE INHIBITOR; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; TROGLITAZONE;

DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SCREENING; WEIGHT GAIN;

EID: 0035944541     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.16.1945     Document Type: Review

References (55)

1. Drug-induced disorders of glucose tolerance
2. Drug-induced disorders of glucose metabolism: Mechanisms and management
3. Impaired granulocyte adherence: A reversible defect in host defense in patients with poorly controlled diabetes
4. Infection and diabetes: The case for glucose control
5. Wound healing with diabetes mellitus: Better glucose control for better wound healing in diabetes
6. Perioperative management of the diabetic patient
7. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
8. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men
9. Is hyperglycemia associated with cardiovascular disease? The Framingham Study
10. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium
11. Effects of beta blocking agents on insulin secretion and glucose disposal
12. Management of patients with hypertension and diabetes mellitus: Advances in the evidence for intensive treatment
13. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study
14. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension: A randomized controlled trial
15. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension: Effect on plasma glucose glucose tolerance
16. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus
17. Diabetes mellitus in treated hypertension: Incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden
18. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
19. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy
20. HIV disease and the endocrine system
21. Severe hyperglycemia in an HIV clinic: Preexisting versus drug-associated diabetes mellitus
22. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
23. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
24. Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
25. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
26. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy
27. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus
28. Management of adverse effects of antiretroviral therapy and medication adherence
29. How to manage metabolic complications of HIV therapy: What to do while we wait for answers
30. Clinical practice recommendations 2001
31. Atypical antipsychotic agents and diabetes mellitus
32. Diabetes mellitus in schizophrenic patients
33. Hyperglycemia associated with olanzapine
34. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
35. Insulin-resistant hyperglycemia induced by clozapine
36. Severe hyperglycemia associated with high doses of clozapine
37. Clozapine and associated diabetes mellitus
38. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
39. Diabetes as a result of atypical anti-psychotic drugs - A report of three cases
40. The effect of clozapine on glucose metabolism
41. Novel antipsychotics and new onset diabetes
42. New-onset diabetes mellitus associated with quetiapine
43. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
44. Olanzapine-induced glucose dysregulation
45. Adverse events related to olanzapine
46. Hyperglycemia and olanzapine
47. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
48. Diabetic ketoacidosis associated with risperidone treatment?
49. Ketoacidosis as a side effect of clozapine: A case report
50. Diabetic ketoacidosis associated with clozapine treatment
51. Diabetic ketoacidosis from clozapine and lithium cotreatment
52. Diabetic ketoacidosis with olanzapine treatment
53. Olanzapine-induced ketoacidosis with diabetes mellitus
54. The apparent effects of ziprasidone on plasma lipids and glucose